Document is current

Article History

Received: 18 December 2024

Accepted: 9 June 2025

First Online: 16 June 2025

Declarations

:

: Human primary fibroblasts (NF1, NF2, FB1, FB2) derived from NSCLC adenocarcinoma patients were generated and kindly provided by the Translational Research Unit of the Thoraxklinik (Heidelberg, Germany) following written informed consent and approval by the ethics committee of the Medical Faculty Heidelberg (S-270/2001, S-296/2016, and S-435/2019, respectively).

: Not applicable.

: M.A.S. reports personal fees from the German Canter for Lung Research (DZL), outside the submitted work. M.T. reports advisory board honoraria from Novartis, Lilly, BMS, MSD, Roche, Celgene, Takeda, AbbVie, and Boehringer; speaker honoraria from Lilly, MSD, and Takeda; research funding from AstraZeneca, BMS, Celgene, Novartis, and Roche; and travel grants from BMS, MSD, Novartis, and Boehringer outside the submitted work. P.C. reports research funding from AstraZeneca, Novartis, Roche, and Takeda as well as advisory board and/or lecture fees from Boehringer Ingelheim, Chugai, Lilly, Pfizer, and Takeda, outside the submitted work. H.S. reports grants from Roche Sequencing Solutions during the conduct of the study and personal fees from Roche outside the submitted work. A.K.D., L.S., T.M., U.K., and A.S. declare no competing interests.